CARLSBAD, Calif., April 27 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announces the following webcast:
What: ISIS 301012 Phase 2 Data When: Friday, April 28, 2006, at 8:30 a.m. ET / 5:30 a.m. PT Where: www.isispharm.com How: Live on the Internet. Simply log onto our website listed above. Contact: Navjot Rai Corporate Communications (760) 603-2331
If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world’s first antisense drug and has 15 drugs in development. Isis’ drug development programs are aimed at treating cardiovascular, metabolic and inflammatory diseases. Isis’ partners are focused in disease areas such as inflammatory, ocular, viral and neurodegenerative diseases, and cancer. In its Ibis division, Isis is developing and commercializing the IBIS biosensor system, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of approximately 1,500 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.
This webcast includes forward-looking statements regarding the development, therapeutic potential of ISIS 301012 to lower high cholesterol as well as the drug’s safety profile. Any statement describing Isis’ goals, expectations, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis’ goals. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a business around such products. Isis’ forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis’ forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis’ programs are described in additional detail in Isis’ annual report on Form 10-K for the year ended December 31, 2005, which is on file with the U.S. Securities and Exchange Commission (SEC) and available from the Company.
Isis Pharmaceuticals, Inc.
CONTACT: Navjot Rai, Corporate Communications of Isis Pharmaceuticals,Inc., +1-760-603-2331
Web site: http://www.isispharm.com/
